A systematic review and meta-analysis estimating the differences in bleeding risks between therapeutic-dose non-vitamin K oral anticoagulants (NOACs) and single antiplatelet therapy (aspirin) found ...

Background Anticoagulation therapy reduces stroke risk in patients with atrial fibrillation (AF), but it is often underused ...

Within the legacy portfolio, higher sales of Eliquis were offset by the expected ... We've also seen a number of NCCN guidelines updated for your reimbursement question to include Opdivo Qvantig ...

We now have a glimpse behind the curtain of how Medicare arrives at so-called maximum fair prices of prescription drugs it ...

Experts discuss PPI use for GI protection in patients on antithrombotics, highlighting risk factors, dosing, drug ...

Background Differences in the clinical outcomes and level of risk among Asian versus non-Asian patients with atrial ...

With these anticipated label enhancements, EYLEA HD will offer the broadest set of retinal disease indications with the greatest dose and flexibility ... non-inferior to apixaban, while REGN9933 ...

8 In the ATLANTIS 4D CT trial, there was evidence that the use of OAC with apixaban and VKA decreased the ... 7 The ACC/AHA valvular heart disease guideline recommends urgent treatment with low-dose ...

Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed ... and has been administered in a twice-daily dosing regimen in clinical trials without the need for ...

Medicare typically covers Eliquis through Medicare Advantage Part C or Medicare Part D prescription drug coverage plans. The cost of Eliquis can depend on the type of plan, the formulary tier ...